Overview

Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC

Status:
Not yet recruiting

Trial end date:
2021-12-31

Target enrollment:

Participant gender:

Summary

Evaluate the efficacy and safety of Anlotinib Hydrochloride in combination with Pemetrexed and Carboplatin versus Pemetrexed and Carboplatin for advanced or locally-advanced Osimertinib-resistant non-squamous non-small cell lung cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Carboplatin
Osimertinib
Pemetrexed